European Journal of Rheumatology
Original Article

The relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis

1.

Department of Nutrition and Dietetic, Gazi University, Ankara, Turkey.; Department of Health Sciences, California Baptist University, Riverside, California, USA

2.

Department of Nutrition and Dietetic, Gazi University, Ankara,Turkey.

Eur J Rheumatol 2018; 5: 1-4
DOI: 10.5152/eurjrheum.2017.17287
Read: 2121 Downloads: 1062 Published: 03 September 2019

Abstract

 

Objective: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS).

 

Methods: Serum endocan levels were analyzed in 42 patients with AS under anti-TNF-alpha usage. Control group consisted of 37 patients with AS who are not receiving anti-TNF drugs. Endocan is analyzed using ESM-1 ELISA kits. The blood glucose and lipid measurements of patients were also assessed.

 

Results: There was no significant change in serum endocan levels among groups. The total cholesterol, triglyceride, and LDL-C levels were higher in patients receiving anti-TNF-alpha; however, differences were not significant. There was no significant correlation between serum endocan levels and blood lipid measurements.

 

Conclusion: Anti-TNF-alpha treatment does not affect serum endocan levels in patients with AS. This research has been first to evaluate the relationship between serum endocan and anti-TNF-alpha therapy in AS. Future studies are necessary to verify the exact role of anti-TNF-alpha therapy on serum endocan levels in patients with AS.

 

Cite this article as: Kadayıfçı FZ, Gezmen Karadağ M. The relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis. Eur J Rheumatol 2018; 5: 1-4.

Files
EISSN 2148-4279